Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiology, heart failure, electrophysiology, hypertension, structural heart disease, use of pharmaceuticals, and COVID-19.

Johnson & Johnson gains CE mark approval for catheter capable of radiofrequency, PFA ablation
A new catheter from Johnson & Johnson MedTech is now approved to treat cardiac arrhythmias in Europe. Could FDA approval be on the horizon?
Robotic mitral repair compares favorably to surgery—but some concerns remain
Robotic-assisted mitral valve repair is associated with short-term outcomes comparable to conventional surgery, according to a new analysis of more than 40,000 patients. Robotic treatment also helps patients spend less time in the hospital, but the costs are much higher.
FDA has now cleared more than 1,000 AI models, including many in cardiology
Cardiology is the medical speciality with the second most FDA clearances overall.
Altered brain structure may play a role in eating disorders, MRI data suggest
Experts recently uncovered evidence suggesting behaviors such as undereating, binging and purging could be owed to anatomical alterations in parts of the brain.
Johnson & Johnson pauses use of FDA-approved PFA system to investigate patient complications
Johnson & Johnson MedTech's Varipulse PFA system has been linked to multiple reports of "neurovascular events" in patients. The company hopes to share more information in the days ahead.

CDK2 inhibitors protect cancer patients from anthracycline-induced cardiotoxicity

Inhibiting a certain class of cyclin-dependent kinase (CDK) proteins could protect cancer patients from chemotherapy-induced heart failure—the second leading cause of death in the demographic after cancer recurrence—according to research published in the Journal of Biological Chemistry.

November 7, 2018

New Data Continue to Reinforce IN.PACT Admiral DCB as a Durable, Frontline Option to Address Treatment Challenges in PAD

Medtronic data presented today reinforce the durability, safety, and effectiveness of the IN.PACT Admiral drug-coated balloon (DCB) in patients with peripheral artery disease (PAD) in the superficial femoral (SFA) and popliteal arteries.

November 6, 2018

The Eluvia drug-eluting stent continues to demonstrate positive outcomes in long lesion IMPERIAL sub-study

Boston Scientific announced clinical outcomes from the IMPERIAL Long Lesion Sub-study demonstrating that the Eluvia Drug-Eluting Vascular Stent System is safe and effective in treating patients with long, complex, calcified lesions within the superficial femoral and proximal popliteal arteries.

November 6, 2018

Cardiology societies produce new bradycardia guideline

The American College of Cardiology, American Heart Association and Heart Rhythm Society on Nov. 6 released a new guideline for the evaluation and treatment of patients with bradycardia and cardiac conduction disorders.

November 6, 2018

Cannabis linked to double the risk of ketoacidosis in T1D

Cannabis use is associated with double the risk of diabetic ketoacidosis among patients with type 1 diabetes, according to a research letter published Nov. 5 in JAMA Internal Medicine.

November 6, 2018

Diabetes drug metformin could protect against macular degeneration

A 13-year study of type 2 diabetes patients has found metformin, one of the world’s highest-grossing anti-diabetic medications, could be protective against age-related macular degeneration, a leading cause of blindness in Americans older than 50.

November 6, 2018

Fewer antibiotic prescriptions, more IE cases followed guideline update

Antibiotic prescriptions to prevent infective endocarditis (IE) decreased following a 2007 guideline update from the American Heart Association—even among high-risk patients for whom antibiotics were still recommended. Those patients showed an estimated 177 percent increase in IE incidence over the next several years, according to a new study.

November 6, 2018

Study shows potential harms of BP drugs for low-risk, mild hypertension

Low-risk patients with mild hypertension derived no protective benefit from blood pressure drugs over 5.8 years of follow-up but had an increased risk of adverse effects potentially related to the medication, researchers reported in a new study.

November 6, 2018

Clinical

Johnson & Johnson gains CE mark approval for catheter capable of radiofrequency, PFA ablation

Robotic mitral repair compares favorably to surgery—but some concerns remain

FDA has now cleared more than 1,000 AI models, including many in cardiology

Altered brain structure may play a role in eating disorders, MRI data suggest

Johnson & Johnson pauses use of FDA-approved PFA system to investigate patient complications